[
    [
        {
            "time": "",
            "original_text": "疫苗股午后异动，康希诺涨超4%",
            "features": {
                "keywords": [
                    "疫苗",
                    "康希诺",
                    "涨超4%"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "疫苗股午后异动，康希诺涨超4%",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "【券商聚焦】交银维持复星医药(02196)买入评级 指业绩稳健增长且研发进展顺利",
            "features": {
                "keywords": [
                    "复星医药",
                    "买入评级",
                    "业绩稳健增长",
                    "研发进展顺利"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【券商聚焦】交银维持复星医药(02196)买入评级 指业绩稳健增长且研发进展顺利",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "三季度营收超100亿，复星医药抗住降价压力业绩持续增长",
            "features": {
                "keywords": [
                    "复星医药",
                    "三季度营收",
                    "业绩持续增长",
                    "降价压力"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "三季度营收超100亿，复星医药抗住降价压力业绩持续增长",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "纳微科技(688690)：业绩持续高增长 引进归国核心技术人才研发实力进一步增强",
            "features": {
                "keywords": [
                    "纳微科技",
                    "业绩持续高增长",
                    "核心技术人才",
                    "研发实力增强"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "科技",
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "纳微科技(688690)：业绩持续高增长 引进归国核心技术人才研发实力进一步增强",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "三个月股价腰斩，疫苗救不了复星医药",
            "features": {
                "keywords": [
                    "复星医药",
                    "股价腰斩",
                    "疫苗"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "三个月股价腰斩，疫苗救不了复星医药",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "伴随诊断白热化，MRD检测如何能成为肿瘤NGS企业的第二曲线？",
            "features": {
                "keywords": [
                    "伴随诊断",
                    "MRD检测",
                    "肿瘤NGS企业",
                    "第二曲线"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "伴随诊断白热化，MRD检测如何能成为肿瘤NGS企业的第二曲线？",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "信达达伯舒Q3销售额创新高；复星医药公布2021Q3财报",
            "features": {
                "keywords": [
                    "信达达伯舒",
                    "Q3销售额创新高",
                    "复星医药",
                    "2021Q3财报"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "信达达伯舒Q3销售额创新高；复星医药公布2021Q3财报",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]